Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies.
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility.
Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice.
Dr. Boccia describes cases in which he uses CancerTREATMENT NGS+ in his clinical practice.
Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer IndexSM (BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years.
Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer IndexSM (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy.
Dr Susan K. Boolbol talks about the importance of objective evidence provided by the Breast Cancer IndexSM (BCI) in treatment decision making.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the importance of using a clinically validated test such as the Breast Cancer IndexSM (BCI) and its impact on patient confidence in their treatment plan.
Page 1 of 2
Results 1 - 10 of 11
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME